22 November 2022
Researchers in St. Petersburg have come up with what they say is an “effectual” drug candidate to treat Alzheimer’s related degenerative cerebral dysfunctions. The St. Petersburg Institute of Bioregulation and Gerontology and the Pavlov Institute of Physiology are behind the research effort.
As they experimented with Alzheimer’s mouse models, the scientists found out that using special peptides could help prevent and even reverse in the test mice’s brains the loss of what physiologists refer to as dendritic spines – special postsynaptic structures that are responsible for memory mechanisms and particularly involved in forming new memories – thus having cerebral functions fully restored.
The peptide candidate is considered “unique” and safe as no side effects have been reported.
October 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
Novel nanoemulsion-based delivery of antimycobacterial drug
31 October 2024
Russia will create a National Center for Genetic Resources of Microorganisms
31 October 2024
Optimising drug release of personalised 3D printed tablets
30 October 2024
Immunotherapy treatment enhances lymphoma survival, landmark study shows
30 October 2024